COVID-19: Information on ASPIRA LABS Operations

Click to Learn More
  • Home
  • Recent News and Upcoming Events

Recent News and Upcoming Events

Recent News


  • Vermillion Announces Reimbursement Code Updates for Overa and OVA1

    vrml_01-09-2016-overa-pla-code__-final Vermillion Announces Reimbursement Code Updates for Overa and OVA1   AUSTIN, Texas, January 9, 2017 — Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company, today announced that the company and its wholly owned subsidiary, ASPiRA Labs, have received a Proprietary Laboratory Analyses (PLA) code (0003U) for Overa (MIA2G), Vermillion’s second-generation FDA cleared Multivariate Index…

  • Vermillion and ASPiRA LABS’ Announce Receipt of Formal FDA Clarification Regarding Ovarian Cancer Screening Alert

    vrml-01-04-2017-fda-clarification-release-_-final   Vermillion and ASPiRA LABS’ Announce Receipt of Formal FDA Clarification Regarding Ovarian Cancer Screening Alert     AUSTIN, Texas, January 4, 2017, Vermillion (NASDAQ: VRML) and ASPiRA LABS, a Vermillion company, today announced the receipt of an FDA Clarification Letter regarding OVA1 (MIA) and Overa (MIA2G). This letter (see attached) is in reference…

  • Vermillion Announces Appointment of Chief Medical Officer

      AUSTIN, Texas — Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company today announced that Marra Francis, MD has been appointed to the position of Chief Medical Officer as of November 8th. Dr. Francis is a board certified Obstetrician and Gynecologist with over 13 years of clinical experience in both Private Practice and the Women’s Health…

  • Vermillion to Present Corporate Overview at the Canaccord Genuity Medical Technology and Diagnostic Forum

        AUSTIN, Texas — Vermillion, Inc. (NASDAQ: VRML) a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer of Vermillion, Inc., will present a corporate overview at the Canaccord Genuity Medical Technology and Diagnostics Forum Conference. Medical Technology & Diagnostics Forum  Date: Thursday, November 17, 2016…

  • Vermillion Reports Third Quarter 2016 Results

      AUSTIN, Texas —  Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported its financial results for the third quarter ended September 30, 2016. Valerie Palmieri, President and CEO of Vermillion, Inc., stated, “We continued to execute on our short-term and long-term goals, including reimbursement, publications, and awareness, as well as…

Investor Relations